Novo Nordisk stated that post hoc analyses of its CagriSema REDEFINE 1 trial are hypothesis-generating and require further study to confirm the results

Overview Debates Related claims Topics Sources

From the articleNovo's CagriSema helped women lose 25% of weight on average, analysis shows | ReutersAlso in Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

552c7ae14Article

Novo's CagriSema helped women lose 25% of weight on average, analysis shows | Reuters

552c7ae14Article

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis